Nektar Therapeutics

https://www.nektar.com/

Nektar Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, focused on discovering and developing novel medicines that address immunological dysfunction in autoimmune and chronic inflammatory diseases. The company leverages its expertise in immunology to design immunomodulatory drugs aimed at enhancing, regulating, or suppressing immune activity to achieve targeted clinical benefits.

Nektar's primary product candidate is rezpegaldesleukin (REZPEG, or NKTR-358), a first-in-class regulatory T cell stimulator currently undergoing Phase 2b clinical trials for atopic dermatitis and alopecia areata, and a Phase 2 clinical trial for Type 1 diabetes mellitus. The pipeline also includes preclinical programs such as NKTR-0165 and NKTR-0166, bivalent antibody programs targeting autoimmune and rheumatic disorders, respectively, and NKTR-422 for inflammation resolution. Additionally, Nektar is evaluating NKTR-255, an IL-15 receptor agonist, in several clinical trials for cancer in collaboration with partners.

Recent notable activities for Nektar Therapeutics include several public offerings in April 2026, which raised significant capital. The company reported its fourth quarter and full-year 2025 financial results in March 2026 and is scheduled to announce first-quarter 2026 results in May 2026. Positive Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata have supported plans for Phase 3 studies to commence in the second quarter of 2026. Howard W. Robin serves as the President and Chief Executive Officer.

Latest updates

Nektar Schedules Q1 Earnings Call Amid Pipeline Scrutiny

Event summary

  • Nektar Therapeutics will release its Q1 2026 financial results after market close on May 7, 2026.
  • CEO Howard Robin will host a conference call at 5:00 PM Eastern Time/2:00 PM Pacific Time.
  • The earnings call webcast and related materials are accessible via the company's investor relations website.
  • Nektar's lead candidate, rezpegaldesleukin (REZPEG/NKTR-358), is in Phase 2b trials for atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.

The big picture

Nektar's valuation is intrinsically tied to the success of its lead candidate, REZPEG, in addressing significant unmet needs in autoimmune and inflammatory diseases. The company faces the typical risks associated with clinical-stage biotechnology, including regulatory hurdles and competitive pressures from larger pharmaceutical companies with established immunology franchises. The upcoming earnings call will provide a crucial update on the progress of these trials and the company's overall financial health.

What we're watching

Clinical Progress
The success of Nektar's pipeline hinges on the Phase 2b trials; investor sentiment will be heavily influenced by any data presented during the earnings call regarding REZPEG's efficacy and safety.
Financial Runway
Given the clinical-stage nature of Nektar's business, the company's cash burn rate and remaining financial runway will be critical indicators of its long-term viability.
Pipeline Expansion
The company's progress in preclinical programs, particularly the TNFR2 antibody and bispecific programs, will be scrutinized as a potential source of future revenue and a hedge against REZPEG's trial outcomes.

Nektar Therapeutics Lands $373.8 Million in Public Offering

Event summary

  • Nektar Therapeutics completed a public offering of common stock, raising approximately $373.8 million in gross proceeds.
  • The offering consisted of 4,062,500 shares, including 529,891 shares purchased by underwriters through the exercise of an over-allotment option.
  • The shares were priced at $92.00 per share.
  • Jefferies, TD Cowen, Piper Sandler, and Citigroup served as joint bookrunning managers for the offering.
  • The offering was conducted under a shelf registration statement filed with the SEC on November 12, 2025.

The big picture

Nektar's successful offering underscores the continued investor appetite for clinical-stage biotechnology companies with promising immunology therapies. The substantial capital raise provides a significant runway for clinical development, but also increases the pressure to deliver positive clinical data and demonstrate a clear path to commercialization. The offering's size suggests a degree of confidence in Nektar's pipeline, but also highlights the need for disciplined execution to justify the valuation.

What we're watching

Capital Allocation
The influx of capital will likely accelerate Nektar’s clinical trial timelines for rezpegaldesleukin and other pipeline candidates, but investors should monitor burn rate and the efficiency of resource deployment.
Share Dilution
The significant share increase will dilute existing shareholders; the market's reaction will depend on whether Nektar can demonstrate meaningful clinical progress and value creation to offset the dilution.
Clinical Trial Data
The success of rezpegaldesleukin in ongoing Phase 2b trials for atopic dermatitis, alopecia areata, and Type 1 diabetes will be critical in justifying the valuation and attracting further investment.

Nektar Therapeutics Upsizes Public Offering to $325 Million

Event summary

  • Nektar Therapeutics priced an upsized public offering of 3,532,609 shares at $92.00 per share.
  • The offering raised gross proceeds of approximately $325 million, exceeding initial expectations.
  • Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares.
  • Proceeds will be used for general corporate purposes, including Phase 3 clinical trials for rezpegaldesleukin.
  • The offering is expected to close on April 23, 2026.

The big picture

Nektar's upsized offering underscores the continued investor appetite for immunotherapy plays, particularly those with differentiated regulatory T cell modulation approaches. The substantial capital infusion provides a runway for critical Phase 3 trials, but also increases the pressure to deliver positive clinical data and demonstrate a clear path to commercialization. The offering's size suggests a belief in the potential of rezpegaldesleukin, but also highlights the capital intensity of late-stage drug development.

What we're watching

Clinical Execution
The success of rezpegaldesleukin's Phase 3 trials will be critical to justifying the capital raised and driving future valuation, given the substantial investment being made.
Shareholder Dilution
The increased share count will dilute existing shareholders, and the stock's performance will depend on Nektar's ability to deliver on its clinical milestones and create shareholder value.
Capital Allocation
How effectively Nektar deploys the raised capital across its pipeline, beyond rezpegaldesleukin, will determine its long-term growth trajectory and potential for further financing needs.

Nektar Therapeutics to Raise $250 Million in Public Offering

Event summary

  • Nektar Therapeutics announced a public offering of $250 million in common stock and pre-funded warrants.
  • The company has a 30-day option to sell an additional $37.5 million in stock.
  • Proceeds will primarily fund research and development, including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata.
  • The offering is being made under a shelf registration statement filed with the SEC on November 12, 2025.

The big picture

Nektar's decision to pursue a significant public offering underscores the substantial capital requirements of late-stage clinical development, particularly in the competitive immunotherapy space. The move suggests a need to bolster the company’s financial runway to support rezpegaldesleukin's advancement, highlighting the inherent risks associated with drug development. The involvement of Jefferies, TD Cowen, and Piper Sandler indicates a desire to tap into established distribution networks for biotech equity.

What we're watching

Capital Structure
The dilution effect of this offering on existing shareholders warrants close monitoring, particularly given the company's ongoing clinical trial expenses.
Clinical Execution
Success in the Phase 3 trials for rezpegaldesleukin will be critical to justifying the capital raise and maintaining investor confidence.
Market Sentiment
The pricing and ultimate size of the offering will reflect broader investor appetite for clinical-stage biotech companies, potentially signaling shifts in market risk tolerance.

Nektar Data Deepens Alopecia Areata Response, Signals Biologic Shift

Event summary

  • Nektar Therapeutics’ rezpegaldesleukin demonstrated deepening responses in severe-to-very-severe alopecia areata patients in a 52-week extension of the REZOLVE-AA Phase 2b study.
  • 29-31% of patients in the extension arms achieved a SALT Score ≤20 (80%+ scalp coverage) from week 36 to week 52, compared to none in the placebo arm.
  • 94% of patients completed the 52-week treatment extension with a favorable safety profile, consistent with prior reports.
  • The data supports advancing rezpegaldesleukin into late-stage development for alopecia areata, potentially positioning it as a first-line biologic treatment.

The big picture

Nektar’s data suggests a potential paradigm shift in alopecia areata treatment, moving beyond existing therapies with limited efficacy and safety concerns. The success of rezpegaldesleukin hinges on its ability to address the unmet need for a safe and effective systemic treatment option, potentially capturing a significant share of the $160 million global alopecia areata market. The observed deepening of responses over time, as noted by investigators, could be a critical differentiator for rezpegaldesleukin and a key driver of long-term patient adherence.

What we're watching

Regulatory Landscape
The FDA’s receptiveness to a Treg-modulating biologic for alopecia areata, particularly given existing limitations with JAK inhibitors, will be a key indicator of rezpegaldesleukin’s commercial prospects.
Competitive Dynamics
The emergence of rezpegaldesleukin as a potential first-line treatment could significantly disrupt the alopecia areata market and impact the adoption of existing therapies.
Clinical Adoption
The pace at which physicians adopt rezpegaldesleukin, if approved, will depend on its perceived efficacy and safety relative to current treatment options and the availability of long-term data.

Nektar Data Accepted at AAD Signals Progress in Autoimmune Pipeline

Event summary

  • Nektar Therapeutics’ Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis have been accepted for oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
  • The alopecia areata presentation (Abstract 79863) will focus on 36-week efficacy and safety data, presented by David Rosmarin.
  • The atopic dermatitis presentation (Abstract 73858), presented by Raj Chovatiya, will analyze efficacy, safety, and treatment response based on baseline severity.
  • The REZOLVE-AA study enrolled patients across 30 global sites, with significant enrollment from Poland (62%) and Canada (24%).
  • The REZOLVE-AD study, initiated in October 2023, involved 393 patients across 110 global sites, with 68% in Europe.

The big picture

Nektar’s rezpegaldesleukin represents a novel approach to treating autoimmune disorders by stimulating regulatory T cells. The AAD presentations offer a crucial data point in assessing the viability of this strategy, which, if successful, could disrupt the existing market dominated by JAK inhibitors and biologics. The company's Fast Track designations highlight the FDA's interest, but Phase 2 data remain a critical hurdle for broader commercial success.

What we're watching

Clinical Efficacy
The AAD presentations will be scrutinized for statistically significant efficacy signals, particularly given the high failure rate in autoimmune drug development and the enrollment criteria for the alopecia areata trial.
Regulatory Pathway
How the FDA will interpret the Phase 2b data, especially concerning the Fast Track designations, will influence the likelihood of accelerated approval and subsequent commercialization.
Geographic Risk
Nektar's reliance on Poland and Canada for a significant portion of its alopecia areata trial enrollment creates geographic concentration risk that could impact trial outcomes and regulatory acceptance.

Nektar Bolsters Finances, Advances Treg Therapy Pipeline

Event summary

  • Nektar Therapeutics concluded a secondary offering in February 2026, raising $460 million in gross proceeds and an additional $44 million through an ATM offering.
  • The company's 2025 revenue decreased to $55.2 million from $98.4 million in 2024, primarily due to the sale of the Huntsville manufacturing facility and decreased royalty revenue.
  • Rezpegaldesleukin (REZPEG) Phase 2b data demonstrated durable responses in atopic dermatitis and alopecia areata, suggesting potential for complete disease clearance with maintenance dosing.
  • Nektar plans to initiate Phase 3 trials for rezpegaldesleukin in atopic dermatitis in June 2026.

The big picture

Nektar's recent financing and promising Phase 2 data for rezpegaldesleukin represent a significant inflection point for the company, positioning it to compete in the rapidly growing immunology market. The sale of the Huntsville facility signals a shift towards a more asset-light model, focusing on clinical development and strategic partnerships. However, the company's revenue decline underscores the challenges of transitioning to a fully clinical-stage biotech.

What we're watching

Clinical Execution
The success of the upcoming Phase 3 trial for atopic dermatitis will be critical in validating rezpegaldesleukin's efficacy and driving future valuation, and the timeline for data readouts will be closely monitored.
Financial Runway
While the recent financing provides substantial runway, Nektar's ability to manage operating expenses and avoid further dilution will be essential for long-term sustainability.
Pipeline Diversification
The progress of Nektar's TNFR2 agonist antibody and bispecific programs, NKTR-0165 and NKTR-0166, will be important to observe as a potential source of future revenue and diversification beyond rezpegaldesleukin.

Nektar to Intensify Investor Outreach Amid Rezpegaldesleukin Trial Data Anticipation

Event summary

  • Nektar Therapeutics will present at the TD Cowen Healthcare Conference (March 2-4, Boston) and the Jefferies Biotech on the Beach Summit (March 9-11, Miami).
  • The TD Cowen presentation will be webcast on March 4 at 9:10 AM Eastern Time.
  • Management will be available for one-on-one meetings at the Jefferies Summit.
  • Nektar is developing rezpegaldesleukin (REZPEG, or NKTR-358) for autoimmune and inflammatory diseases, currently in Phase 2b trials.
  • The company's pipeline includes preclinical TNFR2 antibody and bispecific programs, and a modified CSF protein.

The big picture

Nektar's increased investor outreach signals a heightened focus on communicating progress and managing expectations surrounding its lead asset, rezpegaldesleukin, as it approaches potential trial data readouts. The company is operating in a crowded immuno-inflammation space, where clinical trial success and strategic partnerships are critical for differentiation. These conferences provide a key opportunity to influence investor perception and secure funding for continued development.

What we're watching

Clinical Data
The content and timing of the presentations will likely be heavily influenced by the ongoing Phase 2b trials for rezpegaldesleukin, and any interim data readouts will be closely scrutinized for efficacy and safety signals.
Meeting Demand
The level of investor interest in securing one-on-one meetings at the Jefferies Summit will indicate the current sentiment surrounding Nektar and its pipeline, particularly given the competitive landscape in immuno-inflammation.
Partner Strategy
Given the ongoing clinical trials for NKTR-255 with partners, management commentary regarding collaboration dynamics and potential milestones will provide insight into the long-term commercialization strategy.

Nektar Collaborates with UCSF, Leveraging TNFR2 Agonism for MS Research

Event summary

  • Nektar Therapeutics has initiated a research collaboration with UCSF and Dr. Stephen Hauser to investigate NKTR-0165, a TNFR2 agonist antibody, for potential treatment of multiple sclerosis (MS).
  • The collaboration will focus on exploring neuroprotection and cell repair mechanisms in MS models, utilizing patient-derived B cells.
  • UCSF will fund and conduct the research, while Nektar will supply NKTR-0165 and retain all rights to the program.
  • Dr. Hauser, a renowned neuroimmunologist and recipient of the 2025 Breakthrough Prize in Life Sciences, will lead the UCSF research team.
  • NKTR-0165 is currently in IND-enabling studies and is being developed for autoimmune and CNS disorders, including MS, vitiligo, and ulcerative colitis.

The big picture

Nektar's collaboration with UCSF represents a strategic move to leverage the expertise of a leading neuroimmunologist and academic institution in the development of novel MS therapies. The focus on TNFR2 agonism addresses a critical unmet need in MS treatment, targeting inflammation and neurodegeneration. This partnership underscores the increasing trend of biopharma companies collaborating with academic institutions to accelerate drug discovery and validation in complex neurological disorders.

What we're watching

Clinical Efficacy
The success of this collaboration hinges on demonstrating meaningful neuroprotective effects of NKTR-0165 in preclinical models, which will be crucial for advancing the program to clinical trials.
Regulatory Pathway
Given the complexity of MS and the existing treatment landscape, Nektar will need to carefully navigate regulatory pathways and demonstrate a clear clinical advantage for NKTR-0165 to achieve approval.
Pipeline Synergy
The learnings from NKTR-0165 development will inform the advancement of Nektar’s TNFR2 bispecific programs, particularly NKTR-0166, and the overall success of this strategy will depend on efficient translation of these insights.

Nektar Therapeutics Lands $460 Million in Public Offering

Event summary

  • Nektar Therapeutics completed a public offering of $460 million in common stock and pre-funded warrants.
  • The offering included the full exercise of underwriters’ option to purchase additional shares, totaling 7,637,931 shares.
  • The shares were sold at $58.00 per share, and pre-funded warrants at $57.9999 each.
  • Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers, with Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers, and B. Riley Securities as manager.

The big picture

Nektar's successful offering underscores the continued investor appetite for innovative immunotherapy plays, particularly those targeting autoimmune and inflammatory diseases. The $460 million raise provides a significant runway for the company to advance its pipeline, but also increases scrutiny on its clinical trial outcomes and capital efficiency. The offering's structure, including pre-funded warrants, suggests a desire to incentivize long-term investor commitment.

What we're watching

Capital Allocation
The substantial capital infusion will likely accelerate clinical trial timelines for rezpegaldesleukin and other pipeline candidates, requiring careful monitoring of burn rate and resource allocation.
Share Dilution
The significant share issuance will dilute existing shareholders; the market will assess whether the anticipated returns from Nektar's pipeline justify this dilution.
Clinical Trial Data
Success of the ongoing Phase 2b trials for rezpegaldesleukin in atopic dermatitis, alopecia areata, and Type 1 diabetes will be critical in sustaining investor confidence and justifying the raised capital.

Nektar Therapeutics Upsizes Public Offering to $400 Million

Event summary

  • Nektar Therapeutics priced an upsized public offering of $400 million in common stock and pre-funded warrants.
  • The offering consists of 6,603,449 shares of common stock at $58.00 per share and 293,103 pre-funded warrants at $57.9999 per warrant.
  • Nektar has a 30-day option to issue an additional 1,034,482 shares at the public offering price.
  • Net proceeds will be used for general corporate purposes, including R&D, clinical development (Phase 3 trials for rezpegaldesleukin), and manufacturing.
  • The offering is expected to close on February 13, 2026.

The big picture

Nektar's significant capital raise underscores the substantial investment required for late-stage clinical development in the biotechnology sector. The upsized offering suggests strong investor demand, but also highlights the financial risk associated with advancing a pipeline of novel immunotherapies. The company's reliance on rezpegaldesleukin for near-term value creation makes its clinical trial outcomes particularly impactful.

What we're watching

Capital Allocation
The company's ability to efficiently deploy the raised capital into Phase 3 trials and manufacturing will be critical for rezpegaldesleukin's commercial prospects and overall valuation.
Share Dilution
The exercise of the underwriters' option to purchase additional shares could further dilute existing shareholders, impacting near-term earnings per share.
Clinical Progress
The success of ongoing Phase 2b trials for rezpegaldesleukin in atopic dermatitis, alopecia areata, and Type 1 diabetes will heavily influence investor sentiment and future funding needs.

Nektar Therapeutics Launches $300M Offering to Fund Rezpegaldesleukin Development

Event summary

  • Nektar Therapeutics announced a public offering of $300 million in common stock and pre-funded warrants.
  • The company has a 30-day option to sell an additional $45 million in stock.
  • Proceeds will primarily fund general corporate purposes, including Phase 3 clinical trials for rezpegaldesleukin.
  • The offering is being led by Jefferies, TD Cowen, and Piper Sandler.
  • The registration statement (333-291466) became effective upon filing on November 12, 2025.

The big picture

Nektar's offering reflects the ongoing capital demands within the clinical-stage biotechnology sector, particularly for companies pursuing complex immunotherapy programs. The size of the offering suggests a significant investment required to advance rezpegaldesleukin through Phase 3, indicating the potential for substantial returns but also considerable risk. The reliance on underwriters like Jefferies, TD Cowen, and Piper Sandler underscores the company's need to access public markets to fund its operations.

What we're watching

Capital Structure
The success of this offering, and the potential for the additional $45 million tranche, will significantly impact Nektar's cash runway and ability to independently fund rezpegaldesleukin's Phase 3 trials.
Clinical Execution
The market will scrutinize the progress and data emerging from the Phase 2b trials for rezpegaldesleukin in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus, as these results will heavily influence investor sentiment.
Share Dilution
Continued reliance on equity financing, as demonstrated by this offering, may lead to ongoing share dilution, potentially impacting existing shareholder value and requiring careful management of capital allocation.

Nektar to Release Atopic Dermatitis Trial Data, Key Pipeline Milestone

Event summary

  • Nektar Therapeutics will release topline results from the 36-week maintenance period of its Phase 2b REZOLVE-AD clinical trial on February 10, 2026.
  • The trial is evaluating rezpegaldesleukin (REZPEG, or NKTR-358) for moderate-to-severe atopic dermatitis.
  • Rezpegaldesleukin is a regulatory T-cell (Treg) proliferator, a novel mechanism for treating immune disorders.
  • The results will be presented during a live webcast and investor call at 8:00 am ET.

The big picture

Nektar's focus on Treg proliferation represents a novel approach to treating autoimmune and inflammatory diseases, a market with significant unmet need and substantial commercial potential. The REZOLVE-AD trial is a key value driver for the company, and its outcome will heavily influence Nektar's valuation and strategic direction. Success in atopic dermatitis could pave the way for broader applications of rezpegaldesleukin in other immune-mediated conditions.

What we're watching

Clinical Efficacy
The topline results will reveal whether rezpegaldesleukin demonstrates sufficient efficacy in atopic dermatitis to warrant further development, a critical factor for investor confidence.
Regulatory Pathway
The trial design and results will influence Nektar's strategy for engaging with regulatory agencies, potentially impacting the timeline and cost of future approvals.
Pipeline Diversification
Nektar's broader pipeline, including NKTR-255 and TNFR2 antibody programs, will be assessed in light of the REZOLVE-AD results, as success or failure here could shift resource allocation.
CID: 376